menu
    • menu

    Company profile for Moderna Therapeutics

    NEW Drugs in Dev: 62
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Moderna is a leader in the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, an entirely new class of medicines that directs the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. With its breakthrough platform, Moderna is creating mRNA medicines for a wide range of diseases and conditions, in many ...
    Moderna is a leader in the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, an entirely new class of medicines that directs the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. With its breakthrough platform, Moderna is creating mRNA medicines for a wide range of diseases and conditions, in many cases by addressing currently undruggable targets or underserved areas of medical need. Moderna is developing its innovative mRNA medicines for infectious diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Moderna TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Technology Sq, Cambridge, Massachusetts 02139, US
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.modernatx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/moderna-/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CureVac Sues Moderna For COVID-19 Vaccine Patent Infringement
    CureVac Sues Moderna For COVID-19 Vaccine Patent Infringement

    26 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7209742

    FIRSTWORD PHARMA
    26 Apr 2026
    Share Share
    Moderna wins EU approval for combined flu, COVID shot
    Moderna wins EU approval for combined flu, COVID shot

    22 Apr 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-wins-eu-approval-combined-flu-covid-shot-older-adults-2026-04-21/

    REUTERS
    22 Apr 2026
    Share Share
    Moderna To Present Data At 2026 ASCO Conference
    Moderna To Present Data At 2026 ASCO Conference

    21 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-21/moderna-announces-data-to-be-presented-at-2026-asco-annual-meeting

    PHARMIWEB
    21 Apr 2026
    Share Share
    Sanofi's new COVID shot tops Moderna's mNexspike in safety trial
    Sanofi's new COVID shot tops Moderna's mNexspike in safety trial

    20 Apr 2026

    // PRESS RELEASE

    https://www.news.sanofi.us/2026-04-18-ESCMID-Sanofis-NUVAXOVID-TM-COVID-19-vaccine-showed-better-tolerability-than-mNEXSPIKE-in-head-to-head-study

    PRESS RELEASE
    20 Apr 2026
    Share Share
    Moderna To Release Q1 2026 Financial Results On May 1
    Moderna To Release Q1 2026 Financial Results On May 1

    15 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-15/moderna-to-report-first-quarter-2026-financial-results-on-friday-may-1-2026

    PHARMIWEB
    15 Apr 2026
    Share Share
    Moderna To Unveil Revaccination Data For Seasonal Flu Vaccine
    Moderna To Unveil Revaccination Data For Seasonal Flu Vaccine

    06 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-06/moderna-to-present-revaccination-data-for-its-investigational-seasonal-influenza-vaccine-and-for-mre

    PHARMIWEB
    06 Apr 2026
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I No...

    Details:

    MRNA-4157 (Intismeran) is a vaccine drug, which is currently being evaluated in Phase III clinical studies for the treatment of carcinoma, non-small-cell lung.


    Lead Product(s): Intismeran,V940,mRNA-4157,MK-3475A,Pembrolizumab

    Therapeutic Area: Oncology Brand Name: mRNA-4157

    Study Phase: Phase IIIProduct Type: Vaccine

    Recipient: Merck & Co

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 07, 2026

    blank

    01

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Intismeran,V940,mRNA-4157,MK-3475A,Pembrolizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Recipient : Merck & Co

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Ber...

    Details : MRNA-4157 (Intismeran) is a vaccine drug, which is currently being evaluated in Phase III clinical studies for the treatment of carcinoma, non-small-cell lung.

    Product Name : mRNA-4157

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    April 07, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

    Details:

    MRNA-1018-H5 is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Influenza, Human.


    Lead Product(s): mRNA-1018-H5

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Vaccine

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 27, 2026

    blank

    02

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : mRNA-1018-H5

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

    Details : MRNA-1018-H5 is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Influenza, Human.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    March 27, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

    Details:

    mRNA-1189 is a vaccine drug, which is currently being evaluated in Phase I clinical studies for the treatment of epstein-barr virus infections.


    Lead Product(s): mRNA-1189

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Vaccine

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 18, 2026

    blank

    03

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : mRNA-1189

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Yea...

    Details : mRNA-1189 is a vaccine drug, which is currently being evaluated in Phase I clinical studies for the treatment of epstein-barr virus infections.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    March 18, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Moderna Partners Recordati to Globalize Propionic Acidemia Therapy (mRNA-3927)

    Details:

    The collaboration aims to advance propionic acidemia research with mRNA-3927, an oligonucleotide targeting PCCA mRNA.


    Lead Product(s): mRNA-3927

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Oligonucleotide

    Sponsor: Recordati

    Deal Size: $160.0 million Upfront Cash: $50.0 million

    Deal Type: Collaboration January 29, 2026

    blank

    04

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : mRNA-3927

    Therapeutic Area : Neurology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Recordati

    Deal Size : $160.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Moderna Partners Recordati to Globalize Propionic Acidemia Therapy (mRNA-3927)

    Details : The collaboration aims to advance propionic acidemia research with mRNA-3927, an oligonucleotide targeting PCCA mRNA.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : $50.0 million

    January 29, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Moderna secures $54.3M funding for bird flu vaccine from global coalition

    Details:

    The funding will support the development of mRNA-1018, a vaccine targeting Hemagglutinin, to address the Bird Flu.


    Lead Product(s): mRNA-1018

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Vaccine

    Sponsor: Global Coalition

    Deal Size: $54.3 million Upfront Cash: Undisclosed

    Deal Type: Funding December 18, 2025

    blank

    05

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : mRNA-1018

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Global Coalition

    Deal Size : $54.3 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Moderna secures $54.3M funding for bird flu vaccine from global coalition

    Details : The funding will support the development of mRNA-1018, a vaccine targeting Hemagglutinin, to address the Bird Flu.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    December 18, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COV...

    Details:

    MRNA-1273 (mRNA-1273) is a Vaccine drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of COVID-19.


    Lead Product(s): Elasomeran

    Therapeutic Area: Infections and Infectious Diseases Brand Name: mRNA-1273

    Study Phase: Phase IVProduct Type: Vaccine

    Sponsor: Tor Biering-Sørensen

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 12, 2025

    blank

    06

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Elasomeran

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Tor Biering-Sørensen

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adult...

    Details : MRNA-1273 (mRNA-1273) is a Vaccine drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of COVID-19.

    Product Name : mRNA-1273

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    December 12, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Cor...

    Details:

    MRNA-1273 (Elasomeran) is a Vaccine drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of COVID-19.


    Lead Product(s): Elasomeran,mRNA-1283

    Therapeutic Area: Infections and Infectious Diseases Brand Name: mRNA-1273

    Study Phase: Phase IVProduct Type: Vaccine

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 05, 2025

    blank

    07

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Elasomeran,mRNA-1283

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Ye...

    Details : MRNA-1273 (Elasomeran) is a Vaccine drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of COVID-19.

    Product Name : mRNA-1273

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    December 05, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    V940 Plus Pembrolizumab and Chemo in Metastatic Lung Cancer Patients

    Details:

    MRNA-4157 (Intismeran Autogene) is a Vaccine drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.


    Lead Product(s): Intismeran Autogene,Pembrolizumab,Carboplatin,Paclitaxel

    Therapeutic Area: Oncology Brand Name: mRNA-4157

    Study Phase: Phase IIProduct Type: Vaccine

    Recipient: Merck & Co

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 28, 2025

    blank

    08

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Intismeran Autogene,Pembrolizumab,Carboplatin,Paclitaxel

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Recipient : Merck & Co

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    V940 Plus Pembrolizumab and Chemo in Metastatic Lung Cancer Patients

    Details : MRNA-4157 (Intismeran Autogene) is a Vaccine drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

    Product Name : mRNA-4157

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    October 28, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Approves Moderna’s Updated COVID-19 Vaccine For LP.8.1

    Details:

    Spikevax 2025-2026 formula has been approved for the prevention of COVID-19 in adults 65 years and older or individuals 12 years.


    Lead Product(s): Elasomeran,COVID-19 Vaccine, mRNA

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Spikevax

    Study Phase: Approved FDFProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 27, 2025

    blank

    09

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Elasomeran,COVID-19 Vaccine, mRNA

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FDA Approves Moderna’s Updated COVID-19 Vaccine For LP.8.1

    Details : Spikevax 2025-2026 formula has been approved for the prevention of COVID-19 in adults 65 years and older or individuals 12 years.

    Product Name : Spikevax

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    August 27, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    mRNA-1345 Safety and Immunogenicity In Adults ≥60 After RSV Subunit Vaccine

    Details:

    MRNA-1345 is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Respiratory Syncytial Virus Infections.


    Lead Product(s): mRNA-1345

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Vaccine

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 12, 2025

    blank

    10

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Moderna Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : mRNA-1345

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    mRNA-1345 Safety and Immunogenicity In Adults ≥60 After RSV Subunit Vaccine

    Details : MRNA-1345 is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Respiratory Syncytial Virus Infections.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    August 12, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Brand Name : Spikevax JN (mRNA-)

    U.S.A
    Stanford Drug Discovery Symposium
    Not Confirmed
    arrow

    Brand Name : Spikevax JN (mRNA-)

    U.S.A
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Allowed

    Registration Country : Switzerland

    SARS-CoV-2 JNJ-792 (mRNA vaccine)

    Moderna Therapeutics

    Dosage Form : Dispersion For Injection

    Brand Name : Spikevax JN (mRNA-)

    Dosage Strength : 0.10mg/dose

    Packaging :

    Approval Date : 09/09/2024

    Application Number : 69788

    Regulatory Info : Allowed

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : SPIKEVAX

    U.S.A
    Stanford Drug Discovery Symposium
    Not Confirmed
    arrow

    Brand Name : SPIKEVAX

    U.S.A
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : SCHEDULE D

    Registration Country : Canada

    *sarscov2 S-protein Mrna, 5'(m7g-5'-ppp-5'-gm), 3'...

    Moderna Therapeutics

    Dosage Form : DISPERSION

    Brand Name : SPIKEVAX

    Dosage Strength : 0.1MG/ML

    Packaging :

    Approval Date :

    Application Number : 2541270

    Regulatory Info : SCHEDULE D

    Registration Country : Canada

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : SPIKEVAX

    U.S.A
    Stanford Drug Discovery Symposium
    Not Confirmed
    arrow

    Brand Name : SPIKEVAX

    U.S.A
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : SCHEDULE D

    Registration Country : Canada

    *sarscov2 S-protein Mrna, 5'(m7g-5'-ppp-5'-gm), 3'...

    Moderna Therapeutics

    Dosage Form : DISPERSION

    Brand Name : SPIKEVAX

    Dosage Strength : 50MCG/0.5ML

    Packaging :

    Approval Date :

    Application Number : 2557770

    Regulatory Info : SCHEDULE D

    Registration Country : Canada

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Nail Wax Jn.1

    U.S.A
    Stanford Drug Discovery Symposium
    Not Confirmed
    arrow

    Brand Name : Nail Wax Jn.1

    U.S.A
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    5'-capped Mrna Encoding Full-length Omicron Varian...

    Moderna Therapeutics

    Dosage Form : Injectable Solution

    Brand Name : Nail Wax Jn.1

    Dosage Strength : 0.1mg/ml

    Packaging :

    Approval Date : 10-09-2024

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Nail Wax Jn.1

    U.S.A
    Stanford Drug Discovery Symposium
    Not Confirmed
    arrow

    Brand Name : Nail Wax Jn.1

    U.S.A
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    5'-capped Mrna Encoding Full-length Omicron Varian...

    Moderna Therapeutics

    Dosage Form : Injectable Solution

    Brand Name : Nail Wax Jn.1

    Dosage Strength : 50mcg

    Packaging :

    Approval Date : 10-09-2024

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Nail Wax Jn.1

    U.S.A
    Stanford Drug Discovery Symposium
    Not Confirmed
    arrow

    Brand Name : Nail Wax Jn.1

    U.S.A
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    5'-capped Mrna Encoding Full-length Omicron Varian...

    Moderna Therapeutics

    Dosage Form : Solution For Injection

    Brand Name : Nail Wax Jn.1

    Dosage Strength : 50mcg

    Packaging :

    Approval Date : 10-09-2024

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    Stanford Drug Discovery Symposium
    Not Confirmed
    arrow

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Denmark

    Andusomeran

    Moderna Therapeutics

    Dosage Form : Injectable Solution

    Brand Name : Spikevax Xbb.1.5

    Dosage Strength : 0.1mg/ml

    Packaging :

    Approval Date : 15-09-2023

    Application Number : 28107037823

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    Stanford Drug Discovery Symposium
    Not Confirmed
    arrow

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Denmark

    Andusomeran

    Moderna Therapeutics

    Dosage Form : Injectable Solution

    Brand Name : Spikevax Xbb.1.5

    Dosage Strength : 50mcg

    Packaging :

    Approval Date : 15-09-2023

    Application Number : 28107038023

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    Stanford Drug Discovery Symposium
    Not Confirmed
    arrow

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Denmark

    Andusomeran

    Moderna Therapeutics

    Dosage Form : Dispersion For Injection

    Brand Name : Spikevax Xbb.1.5

    Dosage Strength : 50mcg

    Packaging :

    Approval Date : 15-09-2023

    Application Number : 28107038123

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Nail Wax Xbb.1.5

    U.S.A
    Stanford Drug Discovery Symposium
    Not Confirmed
    arrow

    Brand Name : Nail Wax Xbb.1.5

    U.S.A
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Andusomeran

    Moderna Therapeutics

    Dosage Form : Injectable Solution

    Brand Name : Nail Wax Xbb.1.5

    Dosage Strength : 0.1mg/ml

    Packaging :

    Approval Date : 15-09-2023

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Europe

    read-more
    read-more

    01

    Brand Name : Spikevax JN (mRNA-)

    U.S.A
    Bioprocess International Europe
    Not Confirmed
    arrow

    Brand Name : Spikevax JN (mRNA-)

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Allowed

    Registration Country : Switzerland

    SARS-CoV-2 JNJ-792 (mRNA vaccine)

    Moderna Therapeutics

    Dosage Form : Dispersion For Injection

    Dosage Strength : 0.10mg/dose

    Packaging :

    Brand Name : Spikevax JN (mRNA-)

    Approval Date : 09/09/2024

    Application Number : 69788

    Regulatory Info : Allowed

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Nail Wax Jn.1

    U.S.A
    Bioprocess International Europe
    Not Confirmed
    arrow

    Brand Name : Nail Wax Jn.1

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    5'-Capped mRNA encoding full-length Omicron varian...

    Moderna Therapeutics

    Dosage Form : Injectable Solution

    Dosage Strength : 0.1mg/ml

    Packaging :

    Brand Name : Nail Wax Jn.1

    Approval Date : 10-09-2024

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Nail Wax Jn.1

    U.S.A
    Bioprocess International Europe
    Not Confirmed
    arrow

    Brand Name : Nail Wax Jn.1

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    5'-Capped mRNA encoding full-length Omicron varian...

    Moderna Therapeutics

    Dosage Form : Injectable Solution

    Dosage Strength : 50mcg

    Packaging :

    Brand Name : Nail Wax Jn.1

    Approval Date : 10-09-2024

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Nail Wax Jn.1

    U.S.A
    Bioprocess International Europe
    Not Confirmed
    arrow

    Brand Name : Nail Wax Jn.1

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    5'-Capped mRNA encoding full-length Omicron varian...

    Moderna Therapeutics

    Dosage Form : Solution For Injection

    Dosage Strength : 50mcg

    Packaging :

    Brand Name : Nail Wax Jn.1

    Approval Date : 10-09-2024

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    Bioprocess International Europe
    Not Confirmed
    arrow

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Denmark

    Andusomeran

    Moderna Therapeutics

    Dosage Form : Injectable Solution

    Dosage Strength : 0.1mg/ml

    Packaging :

    Brand Name : Spikevax Xbb.1.5

    Approval Date : 15-09-2023

    Application Number : 28107037823

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    Bioprocess International Europe
    Not Confirmed
    arrow

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Denmark

    Andusomeran

    Moderna Therapeutics

    Dosage Form : Injectable Solution

    Dosage Strength : 50mcg

    Packaging :

    Brand Name : Spikevax Xbb.1.5

    Approval Date : 15-09-2023

    Application Number : 28107038023

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    Bioprocess International Europe
    Not Confirmed
    arrow

    Brand Name : Spikevax Xbb.1.5

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Prescription

    Registration Country : Denmark

    Andusomeran

    Moderna Therapeutics

    Dosage Form : Dispersion For Injection

    Dosage Strength : 50mcg

    Packaging :

    Brand Name : Spikevax Xbb.1.5

    Approval Date : 15-09-2023

    Application Number : 28107038123

    Regulatory Info : Prescription

    Registration Country : Denmark

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Nail Wax Xbb.1.5

    U.S.A
    Bioprocess International Europe
    Not Confirmed
    arrow

    Brand Name : Nail Wax Xbb.1.5

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Andusomeran

    Moderna Therapeutics

    Dosage Form : Injectable Solution

    Dosage Strength : 0.1mg/ml

    Packaging :

    Brand Name : Nail Wax Xbb.1.5

    Approval Date : 15-09-2023

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Nail Wax Xbb.1.5

    U.S.A
    Bioprocess International Europe
    Not Confirmed
    arrow

    Brand Name : Nail Wax Xbb.1.5

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Andusomeran

    Moderna Therapeutics

    Dosage Form : Injectable Solution

    Dosage Strength : 50mcg

    Packaging :

    Brand Name : Nail Wax Xbb.1.5

    Approval Date : 15-09-2023

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Nail Wax Xbb.1.5

    U.S.A
    Bioprocess International Europe
    Not Confirmed
    arrow

    Brand Name : Nail Wax Xbb.1.5

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Approved

    Registration Country : Sweden

    Andusomeran

    Moderna Therapeutics

    Dosage Form : Solution For Injection

    Dosage Strength : 50mcg

    Packaging :

    Brand Name : Nail Wax Xbb.1.5

    Approval Date : 15-09-2023

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    USDMF

    read-more
    read-more

    01

    SM-102 NOVEL LIPID EXCIPIENT

    BPI Europe
    Not Confirmed
    arrow

    SM-102 NOVEL LIPID EXCIPIENT

    U.S.A
    arrow
    BPI Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Moderna Therapeutics

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 31352

    Submission : 2017-02-27

    Status : Inactive

    Type : IV

    blank

    Excipients Web Link

    Market Place

    02

    SM-86 A NOVEL LIPID EXCIPIEN...

    BPI Europe
    Not Confirmed
    arrow

    SM-86 A NOVEL LIPID EXCIPIEN...

    U.S.A
    arrow
    BPI Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Moderna Therapeutics

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 31194

    Submission : 2016-12-14

    Status : Inactive

    Type : IV

    blank

    Excipients Web Link

    Market Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    FDA

    read-more
    read-more

    01

    FDA Audited

    USA
    PCC
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PCC
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2024-04-19

    Moderna Therapeutics

    City : Norwood

    State : Massachusetts

    Country/Area : U.S.A

    Zip : 2062

    District :

    Center :

    Project Area : Vaccines and Allergenic Products

    District Decision : No Action Indicated

    Inspection End Date : 2024-04-19

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    FDA Audited

    USA
    PCC
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    PCC
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2023-09-21

    Moderna Therapeutics

    City : Norwood

    State : Massachusetts

    Country/Area : U.S.A

    Zip : 2062

    District :

    Center :

    Project Area : Vaccines and Allergenic Products

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2023-09-21

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search